


OptiCor® Unveils Enhanced Version Empowering Clinicians with ACC/AHA 2023 AF Guideline Implementation



Berlin/New York, 23 January 2024

- **The new ACC/AHA 2023 AF Guidelines represent a groundbreaking shift in the approach to individual risk prediction.**
- **OptiCor® stands out as the sole FDA-reviewed Clinical Decision Support Software capable of directly incorporating the latest guideline recommendations.**
- **OptiCor® goes beyond conventional approaches by seamlessly integrating individual risk predictions for stroke, bleeding, and mortality, providing a comprehensive foundation for personalized treatment recommendations.**

Today, tenacio, a leading provider of Clinical Decision Support Software for cardiovascular diseases, announces the launch of its advanced version of OptiCor®, aligning seamlessly with the latest ACC/AHA 2023 Atrial Fibrillation (AF) Guidelines. The upgraded product OptiCor® is poised to revolutionize the landscape of cardiovascular care by incorporating individual annual stroke risk as a pivotal factor in determining oral anticoagulation treatment.

“The ACC/AHA 2023 AF Guidelines introduce a paradigm shift, emphasizing the importance of personalized risk prediction for stroke, particularly in patients with comorbidities such as heart failure and chronic kidney diseases.”, said tenacio’s CEO Dr. Georg van Husen. “This nuanced approach recognizes the complexities of managing diverse patient populations and underscores the critical role of decision support tools like OptiCor®. “

Key highlights of the new OptiCor version include:

- *Individualized Stroke Risk Assessment:* OptiCor now facilitates the implementation of the ACC/AHA 2023 AF Guidelines by calculating the individual annual stroke risk based on a validated risk prediction algorithm, enabling healthcare professionals to tailor treatment plans more precisely.
- *Comprehensive Guidance for Comorbidities:* With an increased focus on patients with comorbidities, such as heart failure and chronic kidney diseases, the new guidelines underscore the need for sophisticated decision support.

OptiCor® rises to the occasion, providing clinicians with a powerful tool to navigate the intricate decision-making process and ensure optimal patient outcomes.

- *Digital Risk Prediction for Guideline Implementation:* OptiCor® remains at the forefront of digital innovation, making it the first platform for implementing the latest ACC/AHA guidelines. Its robust features enable clinicians to seamlessly integrate guideline recommendations into their practice, enhancing efficiency and precision in patient care.
- *Proven Clinical Impact:* Research has demonstrated that transitioning from previous standard-of-care with CHA2DS2-VASc-based recommendations to individual stroke risk-based strategies, as facilitated by OptiCor®, can lead to a significant reduction in mortality by 23%, stroke by 24%, and bleeding by 14%¹. This substantiates the tangible benefits of adopting OptiCor® in clinical settings.

OptiCor®'s enhanced version is a testament to tenacio's commitment to advancing cardiovascular care through cutting-edge technology. By empowering healthcare professionals with the tools they need to implement the latest guidelines effectively, OptiCor® is driving a new era in personalized and evidence-based treatment strategies for patients with atrial fibrillation.

¹ European Heart Journal - Digital Health, Volume 3, Issue 2, June 2022, Pages 181–194,
<https://doi.org/10.1093/ehjdh/ztac011>

For media inquiries, please contact:
Georg van Husen, co-founder & CEO
georg.van_husen@tenac.io
p +49-151-260 74154

tenac.io GmbH

Am Hamburger Bahnhof 2A
10557 Berlin
Germany

tenac.io. Inc.

447 Broadway, 2nd floor
New York, NY 10013
United States
P (212)-252-2168

About tenacio

tenacio is a leading provider of Clinical Decision Support Software for cardiovascular diseases, dedicated to empowering healthcare professionals with innovative tools for personalized patient care. With a focus on integrating the latest guidelines and leveraging advanced digital technologies, our lead product OptiCor® is at the forefront of transforming cardiovascular care.

tenacio is a privately owned company with offices in New York City and Berlin, Germany.

www.tenac.io